Abstract
In this issue of Blood, Roth et al show in a phase 1/2 trial that crovalimab, a subcutaneously administered monoclonal antibody that targets C5, is sa......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
